{"disease":{"id":"prevention-of-covid-19-in-individuals-5-years-of-age-and-older-when-administered-as-a-third-dose-in-a-series-of-the-pfizer-biontech-covid-19-vaccine","name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a third dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a third dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}